SCHEDULE: Prudential Financial Discloses 5.7% Stake in Arcutis

Prudential Financial, Inc. has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 5.7% in Arcutis Biotherapeutics, Inc. as of December 31, 2025.

Summary

• Prudential Financial, Inc. beneficially owns 7,079,926 shares of Arcutis Biotherapeutics, Inc. common stock.
• This ownership represents 5.7% of Arcutis Biotherapeutics' outstanding common stock.
• Prudential Financial holds sole voting power over 45,000 shares and shared voting power over 6,381,022 shares.
• Prudential Financial has sole dispositive power over 45,000 shares and shared dispositive power over 7,034,926 shares.
• The beneficial ownership is primarily held through its subsidiaries: Jennison Associates LLC (5.5% with 6,758,006 shares), The Prudential Insurance Company of America (0.00% with 87,005 shares), and PGIM Quantitative Solutions LLC (0.2% with 234,915 shares).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While a Schedule 13G is a routine disclosure, the continued significant stake by a major institutional investor like Prudential Financial suggests ongoing confidence in Arcutis Biotherapeutics, which can be a positive signal for the market.

Positives

• A significant institutional investor like Prudential Financial holding a 5.7% stake can be viewed as a vote of confidence in Arcutis Biotherapeutics' long-term prospects.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• Prudential Financial, Inc. certifies that, to the best of its knowledge and belief, the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that institutional ownership is a common feature in the biotherapeutics sector, where long-term investment horizons and specialized analysis are often required. A significant stake by a major financial institution like Prudential Financial can signal perceived stability or growth potential within the volatile biotech landscape, potentially attracting further investor interest.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holding by Prudential Financial may positively influence investor sentiment and perception of Arcutis Biotherapeutics' stability and future prospects.

Key Dates

Keywords

Prudential Financial, Arcutis Biotherapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotherapeutics, Jennison Associates, PGIM Quantitative Solutions